RhyGaze AG
PrivateLast Round
Series A
Jan 15, 2025
Total Funding Raised
$97.4M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
RhyGaze AG is a biotechnology company developing optogenetic-based gene therapies for retinal diseases causing blindness.
Sector
Frontier & Industrial Tech
Verticals
Sensors, Smart Manufacturing, IoT Hardware
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RhyGaze AG Comparables
Compare RhyGaze AG with similar companies based on industry and business-model similarity.
RhyGaze AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 15, 2025 | ||||
| Seed | Jul 17, 2024 |
RhyGaze AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series A |
| ARCH Venture Partners | Series A |
| F-Prime Capital | Series A |
| BioGeneration Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2026
Open roles increased to 15, 2.3x the trailing average.
- Aug 10, 2026
Open roles increased to 11, 79% of headcount.
RhyGaze AG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about RhyGaze AG's valuation, stock price, and market status.